Cargando…
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
Afatinib is an oral, irreversible ErbB family blocker that covalently binds to the kinase domains of epidermal growth factor receptor (EGFR), human EGFRs (HER) 2, and HER4, resulting in irreversible inhibition of tyrosine kinase autophosphorylation. Studies in healthy volunteers and patients with ad...
Autores principales: | Wind, Sven, Schnell, David, Ebner, Thomas, Freiwald, Matthias, Stopfer, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315738/ https://www.ncbi.nlm.nih.gov/pubmed/27470518 http://dx.doi.org/10.1007/s40262-016-0440-1 |
Ejemplares similares
-
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019) -
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
por: Schnell, David, et al.
Publicado: (2014) -
Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
por: Wiebe, Sabrina, et al.
Publicado: (2016) -
Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat
por: Czock, David, et al.
Publicado: (2021) -
Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)